Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential.
about
Molecular imaging without radiopharmaceuticals?T1 relaxivity of core-encapsulated gadolinium liposomal contrast agents--effect of liposome size and internal gadolinium concentrationStructural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents.Magnetic resonance in the era of molecular imaging of cancerAn effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrixProtein polymer MRI contrast agents: Longitudinal analysis of biomaterials in vivo.Determining the fate of seeded cells in venous tissue-engineered vascular grafts using serial MRIClearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.Molecular imaging as a tool for translating breast cancer scienceInfluence of Molecular Structure on the In Vivo Performance of Flexible Rod Polyrotaxanes.In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging.Strategies for in vivo imaging of enzyme activity: an overview and recent advances.Gd3+-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic-2-hydroxypropyl-β-cyclodextrin/Pluronic Polyrotaxane as a Long Circulating High Relaxivity MRI Contrast Agent.Polymer platforms for drug delivery and biomedical imagingAlbumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: comparison of two contrast agents for glioblastoma.Multimodal Molecular Imaging: Current Status and Future Directions.
P2860
Q30487686-3275AFD3-8C80-47F3-9ABB-F392324365E7Q33369339-EA8497DF-6ECB-4245-900C-D4706987AF23Q33584654-154B8FB4-A1DF-41D0-9362-CC353B331CD7Q33883070-A8BB6E1D-CB40-41F3-926D-7898FA099C10Q34036970-2C8F4046-1BDD-4750-9A8A-DF356CAFFBF4Q34367708-5A5104C0-4E54-43B7-A093-4CD511D507CDQ35609635-83D2081F-59EA-4C21-853E-14346F0B99A8Q36125194-9FBD53B5-7005-447B-ADF8-32A23D8396B4Q37019264-C8C84C5C-D823-469D-A1E5-F4C6C9E10AC6Q37254486-A4957BB3-C0B3-437D-82F7-EC90C14A1882Q37327721-75F6CDD4-9C0E-4970-B8FF-F72AFF0E7921Q37873318-FBFF76E7-D509-4233-ACD4-7EAE63EF5DEDQ38642313-46A86645-01D4-4722-ADE9-2ED103700158Q41873416-34864CB7-4297-4C48-8E6A-D134062134AEQ48327483-B1CCDD04-B99E-47CC-91D1-33A76B390CCFQ55416268-2068AE3D-0AFC-4DC5-B75B-F721D5AEF546
P2860
Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Gadolinium(III)-based blood-po ...... status and clinical potential.
@en
type
label
Gadolinium(III)-based blood-po ...... status and clinical potential.
@en
prefLabel
Gadolinium(III)-based blood-po ...... status and clinical potential.
@en
P2860
P356
P1476
Gadolinium(III)-based blood-po ...... status and clinical potential.
@en
P2093
Zheng-Rong Lu
P2860
P304
P356
10.1517/17425247.4.2.149
P407
P577
2007-03-01T00:00:00Z